INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 346 filers reported holding INTELLIA THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 1.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $97,735,562 | -15.9% | 3,090,941 | +8.5% | 0.01% | -9.1% |
| Q2 2023 | $116,190,677 | +17.4% | 2,849,207 | +7.3% | 0.01% | 0.0% |
| Q1 2023 | $98,969,866 | +12.6% | 2,655,483 | +5.5% | 0.01% | +10.0% |
| Q4 2022 | $87,858,252 | +2.6% | 2,518,150 | +64.5% | 0.01% | -16.7% |
| Q3 2022 | $85,650,000 | +33.9% | 1,530,551 | +23.8% | 0.01% | +50.0% |
| Q2 2022 | $63,984,000 | -32.0% | 1,236,194 | -4.5% | 0.01% | -38.5% |
| Q1 2022 | $94,109,000 | -47.7% | 1,294,999 | -15.0% | 0.01% | -40.9% |
| Q4 2021 | $180,110,000 | +17.2% | 1,523,253 | +32.9% | 0.02% | +4.8% |
| Q3 2021 | $153,742,000 | +36.1% | 1,146,039 | +64.3% | 0.02% | +40.0% |
| Q2 2021 | $112,968,000 | +178.6% | 697,723 | +38.1% | 0.02% | +150.0% |
| Q1 2021 | $40,554,000 | -36.6% | 505,330 | -57.0% | 0.01% | -40.0% |
| Q4 2020 | $63,998,000 | +171.2% | 1,176,455 | -0.9% | 0.01% | +100.0% |
| Q3 2020 | $23,595,000 | +43.9% | 1,186,833 | +52.2% | 0.01% | +25.0% |
| Q2 2020 | $16,396,000 | +106.6% | 779,991 | +20.2% | 0.00% | +100.0% |
| Q1 2020 | $7,935,000 | -43.2% | 648,852 | -31.9% | 0.00% | -33.3% |
| Q4 2019 | $13,970,000 | +13.4% | 952,266 | +3.2% | 0.00% | 0.0% |
| Q3 2019 | $12,314,000 | -15.4% | 922,387 | +3.7% | 0.00% | -25.0% |
| Q2 2019 | $14,557,000 | -56.6% | 889,261 | -54.7% | 0.00% | -55.6% |
| Q1 2019 | $33,552,000 | +10.1% | 1,964,463 | -12.0% | 0.01% | 0.0% |
| Q4 2018 | $30,470,000 | -46.0% | 2,232,246 | +13.3% | 0.01% | -35.7% |
| Q3 2018 | $56,384,000 | -7.8% | 1,970,057 | -11.8% | 0.01% | -17.6% |
| Q2 2018 | $61,129,000 | +51.8% | 2,234,299 | +17.0% | 0.02% | +54.5% |
| Q1 2018 | $40,282,000 | +537.2% | 1,910,019 | +480.7% | 0.01% | +450.0% |
| Q4 2017 | $6,322,000 | -12.1% | 328,927 | +13.7% | 0.00% | 0.0% |
| Q3 2017 | $7,190,000 | +83.1% | 289,368 | +17.9% | 0.00% | +100.0% |
| Q2 2017 | $3,926,000 | -34.1% | 245,409 | -42.0% | 0.00% | 0.0% |
| Q1 2017 | $5,960,000 | -7.4% | 423,050 | -13.8% | 0.00% | 0.0% |
| Q4 2016 | $6,436,000 | +33.7% | 490,960 | +73.6% | 0.00% | -50.0% |
| Q3 2016 | $4,814,000 | -25.2% | 282,826 | -6.1% | 0.00% | 0.0% |
| Q2 2016 | $6,434,000 | – | 301,358 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |